首页> 外文期刊>European urology >Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
【24h】

Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?

机译:前列腺癌手术管理的变化趋势:过度治疗的终结?

获取原文
获取原文并翻译 | 示例
           

摘要

The use of prostate-specific antigen (PSA) for screening or early detection of prostate cancer (PCa) results in significant stage migration toward more favorable stages and a proven decrease in PCa mortality but is accompanied by substantial rates of overdiagnosis and overtreatment. Acknowledgement of these downsides and endeavors to avoid them have led to substantial changes in treatment patterns. Many centers have reported dramatic changes, with increases in active surveillance (AS) of early cancers and local treatment of advanced disease. To estimate the impact of this development on our radical prostatectomy (RP) series, we analyzed changes in cancer and patient selection over the past 15 yr. Despite a trend toward decreased utilization of RP in Germany, the annual caseload at our institution increased due to regionalization, from 382 RPs in 2000 to 2145 in 2011, and has been stable for the past 3 yr (2106 RPs in 2014). The rate of RPs performed in patients with low-risk PCa, AS candidates, or men with a pure Gleason 6 pattern in the RP specimen dropped from 60%, 38.2%, and 56.2%, respectively, in 2004 to 27%, 14.7%, and 10%, respectively, in 2011-2013. Patients undergoing RP with solely Gleason 6 cancer were younger on average (aged 61 yr) than patients in higher risk groups (aged 65 yr). The rate of histologically insignificant PCa was low, ranging from 1% to 8.8% depending on the definition used. Patient selection is the other important tool used to avoid overtreatment. Long-term other-cause mortality (OCM) should be low in adequately selected RP candidates, and after a minimum follow-up of 15 yr, overall OCM was 14.8%. The OCM rate was 10.2% in men aged <65 yr and 24.3% in men aged >= 65 yr. The current analysis documents a clear shift in utilization of RP toward significant PCa in men with long life expectancy. Based on patient and cancer selection as described, the long-standing discussion of overtreatment with RP might become invalid.
机译:使用前列腺特异性抗原(PSA)筛选或早期检测前列腺癌(PCa)会导致明显阶段向更有利的阶段迁移,并证明PCa死亡率降低,但伴随着大量的过度诊断和过度治疗。对这些缺点的认识和避免这些缺点的努力已导致治疗方式的重大变化。许多中心都报告了巨大的变化,早期癌症的主动监测(AS)和晚期疾病的局部治疗在不断增加。为了评估这种进展对我们的前列腺癌根治术(RP)系列的影响,我们分析了过去15年中癌症和患者选择的变化。尽管德国的RP使用率呈下降趋势,但由于地区化,我们机构的年度病例量有所增加,从2000年的382 RPs增至2011年的2145 RPs,并且在过去三年中一直保持稳定(2014年为2106 RPs)。低风险PCa,AS候选人或具有纯Gleason 6模式的男性的RP样本中RP的发生率分别从2004年的60%,38.2%和56.2%下降到2004年的27%,14.7%和2011年至2013年的10%。仅患有格里森6癌的RP患者平均年龄(61岁)比高风险组的患者(65岁)年轻。组织学上无意义的PCa的比率较低,取决于所用的定义,范围为1%至8.8%。选择患者是避免过度治疗的另一重要工具。在适当选择的RP候选人中,长期其他原因死亡率(OCM)应该较低,并且至少随访15年后,总体OCM为14.8%。 <65岁的男性的OCM率为10.2%,> 65岁的男性为24.3%。当前的分析表明,在预期寿命较长的男性中,RP的使用向明显的PCa转移明显。根据所描述的患者和癌症选择,关于RP过度治疗的长期讨论可能会失效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号